Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gefapixant for acute cough in induced viral URTI
NCT03569033Phase 2Terminated
- Sponsor
- Merck & Co.
- Start
- Jul 2018
- Primary completion
- Oct 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of gefapixant in acute cough, sponsored by Merck & Co.. Started Jul 2018; status: terminated.
02
Drugs
gefapixant
03
Conditions
acute cough
Beyond the preview
Go deeper on NCT03569033.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03569033.